×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ASMB – assembly biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ASMB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/6
08:02 am
asmb
Assembly Biosciences (ASMB) had its price target raised by Guggenheim from $39.00 to $43.00. They now have a "buy" rating on the stock.
Low
Report
Assembly Biosciences (ASMB) had its price target raised by Guggenheim from $39.00 to $43.00. They now have a "buy" rating on the stock.
3/29
01:09 am
asmb
Assembly Biosciences (ASMB) was upgraded by Wall Street Zen from "buy
Low
Report
Assembly Biosciences (ASMB) was upgraded by Wall Street Zen from "buy
3/26
08:02 am
asmb
Assembly Biosciences (ASMB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Medium
Report
Assembly Biosciences (ASMB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
3/19
04:55 pm
asmb
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights [Yahoo! Finance]
Medium
Report
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights [Yahoo! Finance]
3/19
04:38 pm
asmb
Assembly Biosciences: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Assembly Biosciences: Q4 Earnings Snapshot [Yahoo! Finance]
3/19
04:32 pm
asmb
Assembly Biosciences GAAP EPS of -$0.55 beats by $3.01, revenue of $72.3M beats by $35.02M [Seeking Alpha]
Low
Report
Assembly Biosciences GAAP EPS of -$0.55 beats by $3.01, revenue of $72.3M beats by $35.02M [Seeking Alpha]
3/19
04:05 pm
asmb
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
Medium
Report
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
1/23
05:06 am
asmb
Assembly Biosciences (NASDAQ:ASMB) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Assembly Biosciences (NASDAQ:ASMB) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/31
04:25 pm
asmb
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Bjorkquist Jeanette M
Medium
Report
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Bjorkquist Jeanette M
3/31
04:20 pm
asmb
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: White Nicole S
Medium
Report
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: White Nicole S
3/31
04:15 pm
asmb
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Gaggar Anuj
Medium
Report
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Gaggar Anuj
3/31
04:10 pm
asmb
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Delaney William E IV
Medium
Report
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Delaney William E IV
3/31
04:05 pm
asmb
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Okazaki Jason A
Medium
Report
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Okazaki Jason A
3/30
05:35 pm
asmb
Form 8-K ASSEMBLY BIOSCIENCES, For: Mar 24
Medium
Report
Form 8-K ASSEMBLY BIOSCIENCES, For: Mar 24
3/30
06:07 am
asmb
Form EFFECT ASSEMBLY BIOSCIENCES,
Low
Report
Form EFFECT ASSEMBLY BIOSCIENCES,
3/19
05:04 pm
asmb
Form S-3 ASSEMBLY BIOSCIENCES,
Medium
Report
Form S-3 ASSEMBLY BIOSCIENCES,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/12
Assembly Biosciences Announces Pricing of $125 Million Public Offering
41.6%
10/15 Assembly Biosciences Inc (NASDAQ: ASMB) is now covered by analysts at Mizuho. They set a "buy" rating on the stock. 36.7%
8/7 Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer 20.2%
10/16 Here's Why Assembly Biosciences Stock Soared Today [The Motley Fool] 19.3%
9/17 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 16.2%
4/6 Research by Assembly Biosciences and Academic Collaborators Published in Hepatology Indicates cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy 12.3%
7/1 Assembly Biosciences Inc (NASDAQ: ASMB) had its "hold" rating re-affirmed by analysts at Chardan Capital. 9.8%
3/13 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 9.6%
3/26 Form SEC STAFF LETTER ASSEMBLY BIOSCIENCES, 9.2%
6/24 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 7.4%
10/15 Assembly Biosciences Inc (NASDAQ: ASMB) is now covered by analysts at Mizuho. They set a "buy" rating on the stock. 36.7%
8/7 Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer 20.2%
10/16 Here's Why Assembly Biosciences Stock Soared Today [The Motley Fool] 19.3%
9/17 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 16.2%
4/6 Research by Assembly Biosciences and Academic Collaborators Published in Hepatology Indicates cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy 12.3%
7/1 Assembly Biosciences Inc (NASDAQ: ASMB) had its "hold" rating re-affirmed by analysts at Chardan Capital. 9.8%
3/13 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 9.6%
3/26 Form SEC STAFF LETTER ASSEMBLY BIOSCIENCES, 9.2%
6/24 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 7.4%
TOP News Decliners
11/11
Data for Assembly Biosciences’ First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019
-18.2%
10/17 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -11.0%
12/12 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -10.6%
8/9 Form 8-K ASSEMBLY BIOSCIENCES, For: Aug 06 -10.1%
9/24 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.8%
9/27 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. -7.7%
12/13 Form 424B5 ASSEMBLY BIOSCIENCES, -6.1%
5/10 Form SC 13G/A ASSEMBLY BIOSCIENCES, Filed by: EcoR1 Capital, LLC -4.9%
2/14 Form SC 13G/A ASSEMBLY BIOSCIENCES, Filed by: ARMISTICE CAPITAL, LLC -3.9%
6/21 Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China -3.6%
10/17 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -11.0%
12/12 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -10.6%
8/9 Form 8-K ASSEMBLY BIOSCIENCES, For: Aug 06 -10.1%
9/24 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.8%
9/27 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. -7.7%
12/13 Form 424B5 ASSEMBLY BIOSCIENCES, -6.1%
5/10 Form SC 13G/A ASSEMBLY BIOSCIENCES, Filed by: EcoR1 Capital, LLC -4.9%
2/14 Form SC 13G/A ASSEMBLY BIOSCIENCES, Filed by: ARMISTICE CAPITAL, LLC -3.9%
6/21 Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: